Intel’s fourth-quarter and full-year 2025 results read like a company that has stopped the bleeding but still hasn’t found its stride, and the numbers quietly confirm that impression. Revenue of $13.7 billion in Q4, down 4% year over year, capped a flat full year at $52.9 billion, which might sound like resilience until you remember how much restructuring, cost cutting, and … [Read more...] about Intel Q4 2025: Stabilization Without Momentum, AI Narrative Doing the Heavy Lifting
Briefing
PR Bubbles and Forgotten Deals: Why Greenland Will Join Trump’s Archive of Vanishing Announcements
Greenland is already fading, and everyone knows it, even if no one has quite said it out loud yet. The announcement had all the familiar ingredients: dramatic tone, oversized geopolitical framing, and the implication that only Trump could see what others were too weak or too blind to grasp. For a moment it worked, the headlines rolled, social media hummed, and pundits argued … [Read more...] about PR Bubbles and Forgotten Deals: Why Greenland Will Join Trump’s Archive of Vanishing Announcements
Nvidia’s $150 Million Bet on Baseten Is About Control, Not Just Compute
Nvidia’s decision to pour $150 million into Baseten looks, at first glance, like just another late-stage AI infrastructure deal. But read it more carefully and the move feels less like a financial investment and more like a positioning maneuver, the kind companies make when they sense the ground shifting under their feet. Training large models made Nvidia the undisputed king of … [Read more...] about Nvidia’s $150 Million Bet on Baseten Is About Control, Not Just Compute
Maersk Downgraded, Shares Slide — and the Market’s Discomfort With Normality
Maersk’s stock was downgraded to “sell,” and the shares slid accordingly — a clean, visible market reaction that on the surface looks like a straightforward analyst call, but underneath exposes something far more awkward about how markets think. The trigger was not a profit warning, a balance-sheet shock, or operational failure. It was the opposite. Analysts are now pricing in … [Read more...] about Maersk Downgraded, Shares Slide — and the Market’s Discomfort With Normality
Why Beam Therapeutics Inc. Jumped 27%: A Market Reading Beyond the Headline
The sudden 27% surge in Beam Therapeutics Inc did not come from a classic biotech trigger like an earnings beat or a dramatic Phase 3 readout, and that’s precisely what makes the move interesting. This rally was driven less by backward-looking financials and more by a forward-looking repricing of risk. Recent financial reports did not surprise on the upside; in fact, Beam’s … [Read more...] about Why Beam Therapeutics Inc. Jumped 27%: A Market Reading Beyond the Headline